tbuckley/cabot-search huggingface dataset:
On the Need for (Only) High-Quality Clinical Practice Guidelines
Authors: Michael Incze, Joseph S. Ross
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Authors: Geoffrey L. Uy, John Godwin, Michael P Rettig, Norbert Vey, Matthew Foster, Martha L. Arellano, David A. Rizzieri, Max S. Topp, Gerwin Huls, Bob Lowenberg, Giovanni Martinelli, Stefania Paolini, Fabio Ciceri, Matteo Giovanni Carrabba, Carmen Ballesteros-Merino, Carlo B Bifulco, Helene Lelièvre, Ross La Motte-Mohs, Daner Li, Jichao Sun, Kenneth Jacobs, Karen Spohn, Nadia Lonsdale, Kathy Tran, Jan Baughman, Michele Shannon, Bernard Fox, Ezio Bonvini, Jon Wigginton, Jan Davidson-Moncada, John F DiPersio
Journal: Blood (2017)
Liver transplantation for hepatocellular carcinoma: The impact of human immunodeficiency virus infection—21 plus 13
Authors: Umberto Baccarani, Gian Luigi Adani, Marcello Tavio, Pierluigi Viale
Journal: Hepatology (2011)

We read with interest the article by Vibert et al.1 recently published in HEPATOLOGY. The authors described their single-center experience with liver transplantation for hepatocellular carcinoma (HCC) in human immunodeficiency virus (HIV)–positive patients (21 cases) and compared those patients to HIV-negative patients (61 cases) who were also affected by HCC. Because of the higher dropout rate among the HIV-positive patients (23.8% versus 11.4%), HIV infection impaired the results of liver transplantation for HCC on an intent-to-treat basis but had no significant impact on overall survival and recurrence-free survival after liver transplantation. In our center from 2005 to 2010, we performed transplantation for 13 HIV-positive patients affected by HCC. The characteristics of this cohort are reported in Table 1. Unlike Vibert et al.'s patients, none of our patients were dropped from the waiting list. None experienced HCC recurrence, although three patients were outside the Milan criteria at listing (23%); only one of those patients (7.7%) had microvascular invasion. Seventy-seven percent had grade 2 and 23% had grade 3 HCC according to Edmondson-Steiner.2 The mean number and total diameter of the HCC nodules were 2 ± 1 and 46 ± 29 mm, respectively, upon pathological analysis. Before transplantation, all patients were treated with transarterial chemoembolization or combined transarterial chemoembolization and radio frequency ablation; the mean necrosis value was 67% ± 39% for the HCC nodules upon pathological analysis. Finally, the 1-, 3-, and 5-year patient and graft survival rates were 84.6%, 84.6%, and 70.5% and 84.6%, 84.6%, and 84.6%, respectively, with a median follow-up of 35 months (range = 2-73 months). In conclusion, our experience seems to be comparable to the experience reported by Vibert et al. except for the absence of HCC recurrence, which was present in 23.8% of the patients investigated in the French cohort. Umberto Baccarani M.D., Ph.D., F.E.B.S.*, Gian Luigi Adani M.D., Ph.D.*, Marcello Tavio M.D. , Pierluigi Viale M.D. , * Liver Transplant Unit, Department of Medical and Biological Sciences, University of Udine, Udine, Italy, Division of Infectious Disease Ospedali Riuniti of Ancona, Ancona, Italy, nstitute of Infectious Disease University of Bologna, Bologna, Italy.
Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
Authors: David B. Page, Ariel Bulua Bourla, Anthony Daniyan, Jarushka Naidoo, Eric Smith, Melody Smith, Claire Friedman, Danny N. Khalil, Samuel Funt, Alexander N. Shoushtari, Willem W. Overwijk, Padmanee Sharma, Margaret K. Callahan
Journal: Journal for ImmunoTherapy of Cancer (2015)

The pioneers of tumor immunology and cancer immunotherapy, including the late William B. Coley and Lloyd J. Old, have championed the potential for immunotherapy for over a century. Finally, advances in our understanding of the fundamentals of tumor immunology are translating into clinical success, with recent US Food and Drug Administration approval of several immunotherapies that improve clinical outcomes across prostate cancer, metastatic melanoma, non-small cell lung cancer and lymphocytic leukemia. In tandem with these clinical successes, new technologies such as high-throughput DNA/RNA sequencing, genetic engineering, and streamlined ex vivo cell culturing have paved the way for the next generation of immunotherapies and provided new tools for investigating potential biomarkers of response to existing therapies. During the November 2014 Annual Meeting of the Society of the Immunotherapy of Cancer, leaders in tumor immunology and cancer immunotherapy convened at the second annual SITC Primer to review both current knowledge and future directions in the field. Here, we will review the key discussions across a variety of topics, including innate immunity, adaptive immunity, dendritic cells, adoptive T cell therapy, anti-tumor antibodies, cancer vaccines, immune checkpoint blockade, challenges to immunotherapy, monitoring immune responses, and immunotherapy clinical trial design.
Leukocytosis, but Not Thrombocytosis, May Constitute a Prothrombotic Pathway in Women with Ovarian Cancer: A Cohort Study
Authors: Javier Lopez Salazar, Laura A Ramirez Tirado, Nora Gomez Contreras, Oscar Arrieta, Dolores Gallardo, Gabriela Cesarman-Maus
Journal: Blood (2018)
How to prescribe loop diuretics in oedema
Authors: Steven D Anisman, Stephen B Erickson, Nancy E Morden
Journal: BMJ (2019)

### What you need to know

Loop diuretics are commonly prescribed to manage oedema symptoms such as swollen legs or breathlessness and to relieve fluid overload. They are widely recommended by guidelines and organisations such as the National Institute for Health and Care Excellence (NICE) in the UK. The loop diuretics available in the UK are furosemide, bumetanide, and torasemide. But which option is best?

The pharmacokinetics of loop diuretics are well characterised. Studies and trials on humans and animals describe pharmacodynamic differences between loop diuretics. However, there is limited evidence directly comparing them. In particular, there is little and low quality information comparing the clinical outcomes of furosemide with the less commonly chosen alternatives torsemide and bumetanide. This article (box 1) outlines some pharmacokinetic differences between available loop diuretics that may influence loop selection in practice and advises how to dose them effectively.

Box 1 
### How this article was created

We initially wrote this article in response to questions primary care clinicians frequently posed when seeking assistance in managing oedema in patients with heart failure. Evidence was gathered over a 15 year period in response to patient and physician queries regarding the management of oedema and the use of loop diuretics. We …
(19)Regional eruptive neurofibromatosis
Authors: T.A.J. Dawson
Journal: British Journal of Dermatology (1984)

Journal Article (19)Regional eruptive neurofibromatosis Get access T.A.J. Dawson T.A.J. Dawson Craigavon Area Hospital, Craigavon, Northern Ireland Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 111, Issue s26, 1 July 1984, Page 65, https://doi.org/10.1111/j.1365-2133.1984.tb05289.x Published: 01 July 1984
Treatment Issues in Type 1 Diabetes
Authors: Zachary T Bloomgarden
Journal: Diabetes Care (2002)

This is the third in a series of reports on the American Diabetes Association (ADA) 61st Scientific Sessions held in Philadelphia, PA, in June 2001. It covers topics related to the treatment of type 1 diabetes.

In a symposium at the ADA meeting, Charles M. Peterson, Bethesda, MD, gave an overview of noninvasive glucose monitoring, stressing the need to critically evaluate the differing technologies. Since 1995 there have been 8 new drugs, 8 new insulins, and 35 new meters introduced on the market; glucose monitoring is a huge industry that is growing by 15% annually. Peterson asked why there is no noninvasive meter, and answered, “because it’s so difficult!” Wet chemistry, solid-phase reagent chemistry, and electrochemical sensing all require a sample as well as a reagent and therefore are “invasive.” Three general approaches exist for glucose enzyme electrodes, measuring O2 consumption, or measuring H2O2 production, with potential cross reactions from metals and ingested drugs. The latest approach has used a two-step enzymatic reaction in which glucose oxidase reduced by glucose is regenerated to its original form for further sample processing. Problems include sample size and preparation, complicated electronics and processing, response time versus sensitivity, sensor fouling, and effects of oxygen and oxidizing interfering substances, including ascorbic acid, uric acid, and acetaminophen. Humidity effects, stability, precision, accuracy, and membrane issues when the substrate is partitioned into a different compartment are additional factors to be addressed.

Satish K. Garg, Barbara Davis Center, Denver, CO, discussed clinical applications of continuous glucose monitoring, which can overcome the discomfort of multiple fingerstick glucose measurements and allow assessment of the peaks and valleys of glucose levels in patients with diabetes. He noted an important discrepancy between the conventionally treated and intensively treated groups in the Diabetes Control and Complications Trial (DCCT), so …
Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma: a Practall document
Authors: Ioana Agache, Rachel Miller, James E. Gern, Peter W. Hellings, Marek Jutel, Antonella Muraro, Wanda Phipatanakul, Santiago Quirce, David Peden
Journal: Allergy (2018)

Abstract Exposome research can improve the understanding of the mechanistic connections between exposures and health to help mitigate adverse health outcomes across the life span. The exposomic approach provides a risk profile instead of single predictors and thus is particularly applicable to allergic diseases and asthma. Under the PRACTALL collaboration between the European Academy of Allergy and Clinical Immunology ( EAACI ) and the American Academy of Allergy, Asthma, and Immunology ( AAAAI ), we evaluated the current concepts and the unmet needs on the role of the exposome in allergic diseases and asthma.
Abstract 2262: Correlation between number and sites of metastases and differential pretreated EBV DNA load profiles and their effects on outcomes in patients with metastatic nasopharyngeal carcinoma
Authors: Cheng-Lung Hsu, Hung-Ming Wang, Tung-Liang Lin, Yung-Chia Kuo
Journal: Cancer Research (2017)

Abstract Differential overall survival of different organ site metastases in nasopharyngeal carcinoma (NPC) had been reported but the underlying mechanism was unclear. We try to find out the possible mechanism from plasma and tumor tissue markers. Total 178 patients of metastatic NPC were enrolled. Their pre-treatment plasma EBV DNA concentrations and cytokines and tissue macrophage, proliferation and apoptosis markers were determined. The overall patient response rate after treatment was 51.7% and median overall survival (OS) was 19 months. Single organ site metastasis had better outcome than multiple organs involved (median OS: 26 months vs. 16 months) with statistical significance. Among single organ site involved, pure lung metastasis had longer survival than bone or liver involved (median OS: 50 months vs. 21 months vs. 18 months) with P&amp;lt;0.001. Pretreatment plasma EBV DNA concentrations were lower in patients with lung metastasis than bone or liver metastasis in single organ involved group. Plasma IP-10 and MCP-1 expression level correlated with the differential single organ site metastasis OS and EBV DNA load. Liver metastatic tissue had higher macrophage infiltration density and higher proliferation index than lung metastatic group. In single organ site metastasis of NPC, lung involved patients had better outcome than bone or liver metastasis. Low pretreatment plasma EBV DNA load, cytokines expression such as IP-10 and MCP-1, tissue macrophage infiltration, and proliferation index may contribute these results. Citation Format: Cheng-Lung Hsu, Hung-Ming Wang, Tung-Liang Lin, Yung-Chia Kuo. Correlation between number and sites of metastases and differential pretreated EBV DNA load profiles and their effects on outcomes in patients with metastatic nasopharyngeal carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2262. doi:10.1158/1538-7445.AM2017-2262
The Antiresection Activity of the X Protein Encoded by Hepatitis Virus B
Authors: Laifeng Ren, Ming Zeng, Zizhi Tang, Mingyuan Li, Xiaojun Wang, Yang Xu, Yuding Weng, Xiaobo Wang, Huan Wang, Liandi Guo, Bing Zuo, Xin Wang, Si Wang, Jiangyan Lou, Yaxiong Tang, Dezhi Mu, Ning Zheng, Xianhui Wu, Junhong Han, Antony M. Carr, Penelope Jeggo, Cong Liu
Journal: Hepatology (2019)

Chronic infection of hepatitis B virus (HBV) is associated with an increased incidence of hepatocellular carcinoma (HCC). HBV encodes an oncoprotein, hepatitis B x protein (HBx), that is crucial for viral replication and interferes with multiple cellular activities including gene expression, histone modifications, and genomic stability. To date, it remains unclear how disruption of these activities contributes to hepatocarcinogenesis. Here, we report that HBV exhibits antiresection activity by disrupting DNA end resection, thus impairing the initial steps of homologous recombination (HR). This antiresection activity occurs in primary human hepatocytes undergoing a natural viral infection–replication cycle as well as in cells with integrated HBV genomes. Among the seven HBV‐encoded proteins, we identified HBx as the sole viral factor that inhibits resection. By disrupting an evolutionarily conserved Cullin4A–damage‐specific DNA binding protein 1–RING type of E3 ligase, CRL4 WDR70 , through its H‐box, we show that HBx inhibits H2B monoubiquitylation at lysine 120 at double‐strand breaks, thus reducing the efficiency of long‐range resection. We further show that directly impairing H2B monoubiquitylation elicited tumorigenesis upon engraftment of deficient cells in athymic mice, confirming that the impairment of CRL4 WDR70 function by HBx is sufficient to promote carcinogenesis. Finally, we demonstrate that lack of H2B monoubiquitylation is manifest in human HBV‐associated HCC when compared with HBV‐free HCC, implying corresponding defects of epigenetic regulation and end resection. Conclusion: The antiresection activity of HBx induces an HR defect and genomic instability and contributes to tumorigenesis of host hepatocytes.
TCT-622 5 year experience with the Absorb bioresorbable vascular scaffold: The Maasstad Absorb Registry
Authors: Georgios J. Vlachojannis, Pieter C. Smits, Kees-Jan Royaards, Marielle A. Koper, Bianca M. Boxma-de Klerk, Adriaan O. Kraaijeveld, Jochem Wassing, Martin van der Ent
Journal: Journal of the American College of Cardiology (2014)
The Combination of PARP Inhibitors and DNMT Inhibitors Modulates Immune Activity and Suggests a Role for Immune Therapy in AML
Authors: Aksinija A Kogan, Michael Topper, Susannah C Shissler, Michael S Lee, Dominique R Bollino, Eun Yong Choi, Rena G Lapidus, Li Li, Donald Small, Maria R. Baer, Tonya J Webb, Stephen Baylin, Feyruz V. Rassool
Journal: Blood (2018)
All endoscopes are equal, but some are more equal than others
Authors: Matthew Rutter
Journal: Endoscopy (2019)

Two of the key aims of diagnostic colonoscopy are to identify colorectal cancer (CRC) and to prevent CRC by detecting and resecting premalignant polyps. However, it is an imperfect test and patients present with post-colonoscopy CRC due to missed lesions [1]. To minimize this risk, the entire colorectal mucosa needs to be carefully inspected. The detection process is multifaceted.
Impact of TP53 Mutated Subclones in Acute Myeloid Leukemia
Authors: Gabriel Pabst, Katharina Prochazka, Gudrun Pregartner, Frank G. Rücker, Ellen Heitzer, Albert Woelfler, Armin Zebisch, Andrea Berghold, Konstanze Döhner, Heinz Sill
Journal: Blood (2018)
SP0080 Data visualisation: tables and graphs for publication and presentation
Authors: M. Boers
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> This workshop (held both on Thursday and on Friday) is an introduction to the principles of good graph and table design as pioneered by Cleveland<sup>1</sup> and Tufte<sup>2</sup> and updated by Few<sup>3</sup> so that the participant can better answer the following questions: Which of the messages in my research results requires a graph or table? Recognising how graphs improve on simple statistics and convey much more information. Knowing when a table is better, or when to keep the data in the body text. How can I best convey the message? Striving for clear vision by choice of graph, scaling, discrimination of data series, minimising non-data ink, avoiding chart junk. Striving for clear understanding through a balance between data and explanation. Using order, subheadings, formatting and rules to guide your reader through your table data. Is my graph/table truthful? Creating a direct proportion between graph and data quantities, avoiding forms prone to misinterpretation, labels to prevent ambiguity; keeping data in context, avoiding more dimensions in the graph than in the data. Visualisation in Tables is further discussed in my recent article that is freely downloadable.<sup>4</sup> This year's course will extend introductory material available via YouTube clips on the ARD website (ard.com)! Direct link: https://www.youtube.com/playlist?list=PLXU14EQbU_V9JpmolAKsaCC0VjJzbxzAN Note that you can also sign up for a <b>special lecture</b>, "Theory of poster design and presentation" followed by a <b>poster tour</b> after the session, devoted to poster design! Session Title: EULAR Projects – Challenging Projects in Education and Training Date/Time: Saturday 16.06.2018 08:30–10:00 Room: Room: E106/E107 Followed by Poster Tour, signup required! <h3>References</h3> [1] Cleveland WS. <i>The elements of graphing data: Hobart Press</i>, Summit, NJ, USA; 1994. [2] Tufte E. <i>The visual display of quantitative information</i> 2nd ed: Graphics Press, Cheshire, CT, USA; 2001. [3] Few S. <i>Show me the numbers</i>. <i>Designing tables and graphs to enlighten</i> 2nd ed. Analytics Press, Oakland, CA, USA; 2012. [4] Boers M. Graphics and statistics for cardiology: designing effective tables for presentation and publication. Heart2018;104:192–200. http://heart.bmj.com/cgi/content/full/heartjnl-2017-311581 <h3>Disclosure of Interest</h3> None declared
Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial
Authors: Judit KJ Keulen, Aafke Bruinsma, Joep C Kortekaas, Jeroen van Dillen, Patrick MM Bossuyt, Martijn A Oudijk, Ruben G Duijnhoven, Anton H van Kaam, Frank PHA Vandenbussche, Joris AM van der Post, Ben Willem Mol, Esteriek de Miranda
Journal: BMJ (2019)

To compare induction of labour at 41 weeks with expectant management until 42 weeks in low risk women.Open label, randomised controlled non-inferiority trial.123 primary care midwifery practices and 45 hospitals (secondary care) in the Netherlands, 2012-16.1801 low risk women with an uncomplicated singleton pregnancy: randomised to induction (n=900) or to expectant management until 42 weeks (n=901).Induction at 41 weeks or expectant management until 42 weeks with induction if necessary.Primary outcome was a composite of perinatal mortality and neonatal morbidity (Apgar score <7 at five minutes, arterial pH <7.05, meconium aspiration syndrome, plexus brachialis injury, intracranial haemorrhage, and admission to a neonatal intensive care unit (NICU). Secondary outcomes included maternal outcomes and mode of delivery. The null hypothesis that expectant management is inferior to induction was tested with a non-inferiority margin of 2%.Median gestational age at delivery was 41 weeks+0 days (interquartile range 41 weeks+0 days-41 weeks+1 day) for the induction group and 41 weeks+2 days (41 weeks+0 days-41 weeks+5 days) for the expectant management group. The primary outcome was analysed for both the intention-to-treat population and the per protocol population. In the induction group, 15/900 (1.7%) women had an adverse perinatal outcome versus 28/901 (3.1%) in the expectant management group (absolute risk difference -1.4%, 95% confidence interval -2.9% to 0.0%, P=0.22 for non-inferiority). 11 (1.2%) infants in the induction group and 23 (2.6%) in the expectant management group had an Apgar score <7 at five minutes (relative risk (RR) 0.48, 95% CI 0.23 to 0.98). No infants in the induction group and three (0.3%) in the expectant management group had an Apgar score <4 at five minutes. One fetal death (0.1%) occurred in the induction group and two (0.2%) in the expectant management group. No neonatal deaths occurred. 3 (0.3%) neonates in the induction group versus 8 (0.9%) in the expectant management group were admitted to an NICU (RR 0.38, 95% CI 0.10 to 1.41). No significant difference was found in composite adverse maternal outcomes (induction n=122 (13.6%) v expectant management n=102 (11.3%)) or in caesarean section rate (both groups n=97 (10.8%)).This study could not show non-inferiority of expectant management compared with induction of labour in women with uncomplicated pregnancies at 41 weeks; instead a significant difference of 1.4% was found for risk of adverse perinatal outcomes in favour of induction, although the chances of a good perinatal outcome were high with both strategies and the incidence of perinatal mortality, Apgar score <4 at five minutes, and NICU admission low.Netherlands Trial Register NTR3431.